Economic impact of the reduced incidence of atrial fibrillation in patients with heart failure treated with enalapril

American Heart Journal

Volumn 150, Issue 5, 2005, Pages 985.e1-985.e8

  Wagner, Monika ^a   Rindress, Donna ^a   Desjardins, Brigitte ^b   Meilleur, Marie Claude ^b   Ducharme, Anique ^c   Tardif, Jean Claude ^c  

^a INSTITUTE FOR RESEARCH IN IMMUNOLOGY AND CANCER   (Canada)

^b MERCK FROSST CENTRE FOR THERAPEUTIC RESEARCH   (Canada)

^c MONTREAL HEART INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; ENALAPRIL; WARFARIN;

ARTICLE; BLEEDING; CANADA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DEATH; EMBOLISM; HEALTH CARE COST; HEALTH CARE PLANNING; HEALTH CARE SYSTEM; HEALTH ECONOMICS; HEALTH STATUS; HEART ATRIUM FIBRILLATION; HEART FAILURE; HOSPITALIZATION; HUMAN; INCIDENCE; PREDICTION; PRIORITY JOURNAL; PROBABILITY; PROPHYLAXIS; RISK FACTOR; SENSITIVITY ANALYSIS; STROKE; TREATMENT OUTCOME;

EID: 27744460734     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2005.07.027     Document Type: Article

References (48)

1. D.G. Manuel, M. Leung, and K. Nguyen Burden of cardiovascular disease in Canada Can J Cardiol 19 2003 997 1004
2. A.U. Khand, J.G. Cleland, and P.C. Deedwania Prevention of and medical therapy for atrial arrhythmias in heart failure Heart Fail Rev 7 2002 267 283
3. G.C. Gronefeld, and S.H. Hohnloser Heart failure complicated by atrial fibrillation: mechanistic, prognostic, and therapeutic implications J Cardiovasc Pharmacol Ther 8 2003 107 113
4. W.H. Maisel, and L.W. Stevenson Atrial fibrillation in heart failure: epidemiology, pathophysiology, and rationale for therapy Am J Cardiol 91 2003 2D 8D
5. M. Pozzoli, G. Cioffi, and E. Traversi Predictors of primary atrial fibrillation and concomitant clinical and hemodynamic changes in patients with chronic heart failure: a prospective study in 344 patients with baseline sinus rhythm J Am Coll Cardiol 32 1998 197 204
6. V. Fuster, L.E. Ryden, and R.W. Asinger ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: executive summary Circulation 104 2001 2118 2150
7. J.G. Cleland, S. Chattopadhyay, and A. Khand Prevalence and incidence of arrhythmias and sudden death in heart failure Heart Fail Rev 7 2002 229 242
8. T.J. Wang, M.G. Larson, and D. Levy Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: the Framingham Heart Study Circulation 107 2003 2920 2925
9. P.E. Carson, G.R. Johnson, and W.B. Dunkman The influence of atrial fibrillation on prognosis in mild to moderate heart failure. The V-HeFT Studies. The V-HeFT VA Cooperative Studies Group Circulation 87 1993 VI102 VI110
10. Lam J, Cote R, Roussin A. Stroke prevention in atrial fibrillation [practical treatment guideline]. Thrombosis Interest Group of Canada. May 2002. Available at: http://www.tigc.org.
11. R. Garg, and S. Yusuf Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials JAMA 273 1995 1450 1456
12. Canadian Cardiovascular Society Heart Failure Guideline Consensus Panel (CCS) The 2002/2003 Canadian cardiovascular society consensus guideline update for the diagnosis and management of heart failure 2003 Canadian Cardiovascular Society Ontario
13. M.I. Wilde, H.M. Bryson, and K.L. Goa Enalapril: a review of quality-of-life and pharmacoeconomic aspects of its use in heart failure and mild to moderate hypertension Pharmacoeconomics 6 1994 155 182
14. A.B. Luzier, A. Forrest, and S.G. Feuerstein Containment of heart failure hospitalizations and cost by angiotensin-converting enzyme inhibitor dosage optimization Am J Cardiol 86 2000 519 523
15. H. Glick, J. Cook, and B. Kinosian Costs and effects of enalapril therapy in patients with symptomatic heart failure: an economic analysis of the Studies of Left Ventricular Dysfunction (SOLVD) Treatment Trial J Card Fail 1 1995 371 380
16. The SOLVD Investigators Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions N Engl J Med 327 1992 685 691
17. The SOLVD Investigators Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators N Engl J Med 325 1991 293 302
18. E. Vermes, J.C. Tardif, and M.G. Bourassa Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction: insight from the Studies Of Left Ventricular Dysfunction (SOLVD) trials Circulation 107 2003 2926 2931
19. P. Jong, S. Yusuf, and M.F. Rousseau Effect of enalapril on 12-year survival and life expectancy in patients with left ventricular systolic dysfunction: a follow-up study Lancet 361 2003 1843 1848
20. J.D. Bentkover, E.J. Stewart, and A. Ignaszewski New technologies and potential cost savings related to morbidity and mortality reduction in class III/IV heart failure patients in Canada Int J Cardiol 88 2003 33 41
21. IMS Health Canadian disease and therapeutic index [database online] 2003 IMS Health Canada Kirkland, Quebec
22. S.A. Hunt, D.W. Baker, and M.H. Chin ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines http://www.acc.org/clinical/guidelines/failure/hf_index.htm 2001 [Accessed 27 Sep 2004]
23. G. Cioffi, M. Pozzoli, and G. Forni Systemic thromboembolism in chronic heart failure. A prospective study in 406 patients Eur Heart J 17 1996 1381 1389
24. D.W. Baker, and R.F. Wright Management of heart failure. IV. Anticoagulation for patients with heart failure due to left ventricular systolic dysfunction JAMA 272 1994 1614 1618
25. W.B. Dunkman, G.R. Johnson, and P.E. Carson Incidence of thromboembolic events in congestive heart failure. The V-HeFT VA Cooperative Studies Group Circulation 87 1993 VI94 VI101
26. F. De Lorenzo, N. Saba, and V.V. Kakkar Blood coagulation in patients with chronic heart failure: evidence for hypercoagulable state and potential for pharmacological intervention Drugs 63 2003 565 576
27. B.F. Gage, A.D. Waterman, and W. Shannon Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation JAMA 285 2001 2864 2870
28. Atrial fibrillation investigators Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials Arch Intern Med 154 1994 1449 1457
29. Atrial fibrillation investigators Echocardiographic predictors of stroke in patients with atrial fibrillation: a prospective study of 1066 patients from 3 clinical trials Arch Intern Med 158 1998 1316 1320
30. R.G. Hart, O. Benavente, and R. McBride Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis Ann Intern Med 131 1999 492 501
31. H.J. Lin, P.A. Wolf, and M. Kelly-Hayes Stroke severity in atrial fibrillation. The Framingham Study Stroke 27 1996 1760 1764
32. B.F. Gage, A.B. Cardinalli, and D.K. Owens Cost-effectiveness of preference-based antithrombotic therapy for patients with nonvalvular atrial fibrillation Stroke 29 1998 1083 1091
33. E. Catherwood, W.D. Fitzpatrick, and M.L. Greenberg Cost-effectiveness of cardioversion and antiarrhythmic therapy in nonvalvular atrial fibrillation Ann Intern Med 130 1999 625 636
34. G.B. Lumer, D. Roy, and M. Talajic Amiodarone reduces procedures and costs related to atrial fibrillation in a controlled clinical trial Eur Heart J 23 2002 1050 1056
35. L. Ceresne, and R.E. Upshur Atrial fibrillation in a primary care practice: prevalence and management BMC Fam Pract 3 2002 11 16
36. N.S. Rawson, J.L. Cox, and M. Stang New use of antiarrhythmia drugs in Saskatchewan Can J Cardiol 18 2002 43 50
37. J.A. O'Brien, A.R. Patrick, and J.J. Caro Cost of managing complications resulting from type 2 diabetes mellitus in Canada BMC Health Serv Res 3 2003 7
38. J.A. O'Brien, I. Caro, and D. Getsios Diabetes in Canada: direct medical costs of major macrovascular complications Value Health 4 2001 258 265
39. M.H. Eckman, R.H. Falk, and S.G. Pauker Cost-effectiveness of therapies for patients with nonvalvular atrial fibrillation Arch Intern Med 158 1998 1669 1677
40. J.R. Butler, and P.J. Fletcher A cost-effectiveness analysis of enalapril maleate in the management of congestive heart failure in Australia Aust NZ J Med 26 1996 89 95
41. W.G. Scott, and H.M. Scott Heart failure. A decision analytic analysis of New Zealand data using the published results of the SOLVD Treatment Trial. Studies of left ventricular dysfunction Pharmacoeconomics 9 1996 156 167
42. C.R. Kerr, J. Boone, and S.J. Connolly The Canadian Registry of Atrial Fibrillation: a noninterventional follow-up of patients after the first diagnosis of atrial fibrillation Am J Cardiol 82 1998 82N 85N
43. J.Y. Le Heuzey, O. Paziaud, and O. Piot Cost of care distribution in atrial fibrillation patients: the COCAF study Am Heart J 147 2004 121 126
44. P.A. Wolf, J.B. Mitchell, and C.S. Baker Impact of atrial fibrillation on mortality, stroke, and medical costs Arch Intern Med 158 1998 229 234
45. W.A. Wattigney, G.A. Mensah, and J.B. Croft Increasing trends in hospitalization for atrial fibrillation in the United States, 1985 through 1999: implications for primary prevention Circulation 108 2003 711 716
46. P.L. L'Allier, A. Ducharme, and P.F. Keller Angiotensin-converting enzyme inhibition in hypertensive patients is associated with a reduction in the occurrence of atrial fibrillation J Am Coll Cardiol 44 2004 159 164
47. A.P. Maggioni, R. Latini, and P.E. Carson Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT) Am Heart J 149 2005 548 557
48. B.N. Singh Atrial fibrillation: epidemiologic considerations and rationale for conversion and maintenance of sinus rhythm J Cardiovasc Pharmacol Ther 8 Suppl 1 2003 S13 S26